
WuXi AppTec, a key player in the drug supply chain, could face challenges as US lawmakers target Chinese biotech companies. Shares of WuXi AppTec and WuXi Biologics rose in Hong Kong after news of Congressman Mike Gallagher's departure, potentially impacting legislation progress.







Shares of Chinese biotechs WuXi Bio and WuXi AppTec rallied on news that Republican Congressman Mike Gallagher, the sponsor of a bill that would block the companies from US contracts, will quit Congress next month https://t.co/pV9WCH6G0K
"In a handful of local court cases around the country, a Shenzhen-based firm has been clandestinely funding intellectual property lawsuits to help upend a major consumer brand." Read Yael Ossowski in @TheNatlInterest. https://t.co/GNvHfJ2XL0
As WuXi Apptec and other Chinese companies have been targeted by US lawmakers, rival manufacturers have quietly — and not so quietly — used the moment to try and gain market share. From @annajbwn and me. https://t.co/cq3GMAwUK0